Have a personal or library account? Click to login
Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study Cover

Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study

Radiology and Oncology
Volume 43 (2009): Issue 4 (December 2009)
By: Dražen Huić,  Andrea Mutvar,  Sandra Kinda-Bašić,  Igor Aurer,  Martina Ciglar,  Darko Grošev,  Ivo Radman,  Boris Labar and  Damir Dodig  
Open Access
|Oct 2009

References

  1. Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 2004; 3: 166-79.10.1053/j.semnuclmed.2004.03.002
    Search in Google Scholar
  2. Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin N Am 2008; 46: 175-98.10.1016/j.rcl.2008.03.005
    Search in Google Scholar
  3. Hoskin PJ. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med 2002; 29: 449-51.10.1007/s00259-001-0755-4
    Search in Google Scholar
  4. Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-4.10.1182/blood.V98.10.2930
    Search in Google Scholar
  5. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.10.1046/j.1365-2141.2001.03147.x
    Search in Google Scholar
  6. Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 307-15.10.1016/S0360-3016(03)00599-6
    Search in Google Scholar
  7. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-78.10.1046/j.1365-2141.2001.03169.x11703321
    Search in Google Scholar
  8. Nordin AJ, Secondino S, Rahim NA, Pedrazzoli P, Siena S, Rossetti C, et al. Imaging in nasopharyngeal carcinoma: the value of 18-Florine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI. Radiol Oncol 2009; 43: 247-57.10.2478/v10019-009-0026-8
    Search in Google Scholar
  9. Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Raja Abdullah RSA. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43: 180-6.10.2478/v10019-009-0023-y
    Search in Google Scholar
  10. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18 FDG - PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.10.1023/A:1008357126404
    Search in Google Scholar
  11. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. 18 F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91: 522-9.
    Search in Google Scholar
  12. Terasawa T, Nihashi T, Hotta T, Nagai H. 18 F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008; 49: 13-21.10.2967/jnumed.107.03986718077527
    Search in Google Scholar
  13. Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET/CT after first line therapy - is biopsy of FDG - avid lesions still needed? Radiology 2007; 244: 257-62.10.1148/radiol.244106081017581905
    Search in Google Scholar
  14. Poulou LS, Karianakis G, Ziakas PD. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease. Eur J Radiol 2009; 70: 499-506.10.1016/j.ejrad.2008.01.04318342471
    Search in Google Scholar
  15. Koga H, Sasaki M, Kuwabara Y, Nakagawa M, Hayashi K, Kaneko K, et al. Lesion detectability of a gamma camera based coincidence system with FDG in patients with malignant tumors: a comparison with dedicated positron emission tomography. Ann Nucl Med 2004; 18: 131-6.10.1007/BF0298510315195760
    Search in Google Scholar
  16. Ak I, Blokland JA, Pauwels EK, Stokkel MP. The clinical value of 18F-FDG detection with a dual-head coincidence camera: a review. Eur J Nucl Med 2001; 28: 763-78.10.1007/s00259010050124777543
    Search in Google Scholar
  17. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 22-8.10.1007/s00259-003-1333-814574514
    Search in Google Scholar
  18. Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin N Am 2008; 46: 225-41.10.1016/j.rcl.2008.04.00218619378
    Search in Google Scholar
  19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-53.10.1200/JCO.1999.17.4.124410561185
    Search in Google Scholar
  20. Grošev D, Lončarić S, Vandenberghe S, Dodig D. Triple-head gamma camera PET: system overview and performance characteristics. Nucl Med Commun 2002; 23: 809-14.10.1097/00006231-200208000-0001612124488
    Search in Google Scholar
  21. Grošev D. Performance characteristics of gamma cameras - Reply. [Letter] Nucl Med Commun 2003; 24: 440.10.1097/00006231-200304000-00016
    Search in Google Scholar
  22. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-94.10.1182/blood-2008-06-155820258198418757777
    Search in Google Scholar
  23. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005; 32: 749-56.10.1007/s00259-004-1748-x15785956
    Search in Google Scholar
  24. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 2007; 48 Suppl 1:19S-27S.
    Search in Google Scholar
  25. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003; 30: S117-27.10.1007/s00259-003-1169-212748831
    Search in Google Scholar
DOI: https://doi.org/10.2478/v10019-009-0024-x | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 258 - 263
Published on: Oct 26, 2009
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Hodgkin's disease,
fluorine-18-fluorodeoxyglucose,
FDG,
PET,
therapy monitoring,
prognosis,
follow-up,
negative predictive value
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2009 Dražen Huić, Andrea Mutvar, Sandra Kinda-Bašić, Igor Aurer, Martina Ciglar, Darko Grošev, Ivo Radman, Boris Labar, Damir Dodig, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 43 (2009): Issue 4 (December 2009)